Navigation Links
Cell Biosciences Strengthens Management Team
Date:7/3/2008

PALO ALTO, Calif., July 3 /PRNewswire/ -- Cell Biosciences, Inc., a provider of ultrasensitive protein detection and characterization systems to life science researchers, today announced three key management team additions.

Jason Novi was named Chief Financial Officer, with responsibility for the finance, manufacturing and administrative functions. Prior to joining Cell Biosciences, Mr. Novi was the Vice President, Finance at Nektar Therapeutics. He served as Director of Finance at Molecular Devices Corporation from 2000 to 2007, where he was responsible for all worldwide accounting, finance and treasury functions, and played a key role in the execution and integration of its corporate development activities.

Robert Gavin was named Vice President, Engineering. Mr. Gavin brings nearly 20 years of experience to the Cell Biosciences development team. Most recently, he served as Director of Engineering at MDS Analytical Technologies (previously Molecular Devices), where he directed multidisciplinary teams of mechanical, electrical, firmware, and systems engineers. Mr. Gavin has a strong record of creating highly-successful laboratory systems, including industry-leading optical plate readers and high throughput screening platforms.

Also announced was the appointment of Wilhelm Lachnit, Ph.D. as Vice President, Research and Development. Dr. Lachnit has two decades of experience in pharma/biotech and life sciences. Most recently, he held both scientific and commercial leadership positions at Molecular Devices, where he played a central role in the development and launch of the IonWorks(TM) product line. Previously, he pioneered the early adoption of automated cell-based assays at Roche and Syntex (acquired by Roche). Dr. Lachnit holds a Ph.D. in Pharmacology-Toxicology from the University of California, Davis.

"I am extremely pleased to announce these additions to the Cell Biosciences leadership team," said Tim Harkness, President and Chief Executive Officer. "These individuals have all been key contributors at successful life science companies. I am confident that they will provide exceptionally strong leadership as we develop our portfolio of ultrasensitive nano-proteomics products."

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nano-proteomics. We are developing instrumentation systems to enable the detection and characterization of specific proteins in extremely small biological samples. Our company's lead product, the Firefly 3000, is a capillary-based nanofluidic immunoassay platform designed for ultrasensitive detection and characterization of proteins. Cell Biosciences is located in Palo Alto, CA. http://www.cellbiosciences.com


'/>"/>
SOURCE Cell Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):